Dediabetes Logo
Centro de evidencia
Descubre que funciona
Evidence Explorer
Busca en el grafo completo de evidencia
Referencia clínica
Dossieres detallados de intervenciones y resultados
Investigacion reciente
Estudios mas recientes
Que cambio
Inteligencia semanal
Configuracion
Entrar / Unirse
Resumen de Investigación
Analyzed using Evidence Intelligence™

Semaglutide improves cardiorenal outcomes in high-risk diabetes patients

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 6 de julio de 2026

Key finding

Semaglutide significantly reduced the risk of primary MACE (HR [95% CI] 0.76 [0.62; 0.92], p = 0.0062).

This study evaluated the cardiorenal effects of semaglutide in individuals with type 2 diabetes at high cardiovascular risk, finding significant reductions in major adverse cardiovascular events.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

High Risk

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated the cardiorenal effects of semaglutide in individuals with type 2 diabetes at high cardiovascular risk, finding significant reductions in major adverse cardiovascular events.

Clinical relevance

These findings are important as they suggest that semaglutide may be an effective treatment option for reducing cardiovascular risks in patients with type 2 diabetes, a population that is often at elevated risk for heart complications. This could lead to improved management strategies for these patients, potentially reducing the burden of cardiovascular disease.

Keep in mind

The study did not show significant effects on cardiovascular death or all-cause mortality. The generalizability of findings may be limited to the specific population studied. Potential confounding factors were not fully explored.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Jingmin Z, Mansoor H, Yang L, et al. Cardiorenal effects of semaglutide in people with type 2 diabetes at high cardiovascular risk. Diabetes, Obesity & Metabolism. 2025;27(10):5706-5715. doi:10.1111/dom.16621

View DOIView on PubMedView on PMC

Efectos Principales

Semaglutide significantly reduced the risk of primary MACE (HR 0.76, p = 0.0062).

Semaglutide significantly reduced the risk of expanded MACE (HR 0.80, p = 0.0097).

Semaglutide consistently reduced nephropathy risk (HR 0.64, p = 0.0054).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide and All-cause mortality, Cardiovascular death, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), and 1 more.

This study contributes evidence to

Intervention

Semaglutide

Outcome

All-cause mortality

Evidence topic

Cardiovascular Risk

Primary intervention

Semaglutide

Primary outcomes

  • All-cause mortality
  • Cardiovascular death
  • Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence topics

Cardiovascular RiskGLP-1 Receptor Agonists

Primary intervention

Semaglutide

Primary outcomes

All-cause mortalityCardiovascular deathComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

4
Evidence pairs
4
Relationships
2
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

2

Related topics

4

Evidence pairs

110

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 4 evidence relationships
  • Includes primary outcome data
  • Linked to 2 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

GLP-1 Receptor Agonists and Cardiovascular Outcomes

Evidencia relacionada

Relación de evidencia

GLP-1 Receptor Agonists and Kidney Function

Guardar evidencia

Tema de evidencia

Cardiovascular Risk

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

All-cause mortality

Semaglutide → All-cause mortality

Semaglutide → All-cause mortality

Evidence Intelligence™
EvidenceScore™
83
Strong
ImpactScore™
67
Slightly Positive
ConsistencyScore™
35
mixed
Estudios de apoyo: Basado en 6 estudios
Add to Evidence Tracker

Cardiovascular death

Semaglutide → Cardiovascular death

Semaglutide → Cardiovascular death

Evidence Intelligence™
EvidenceScore™
77
Strong
ImpactScore™
33
Slightly Negative
ConsistencyScore™
67
generally_consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence Tracker

Nephropathy progression

Semaglutide → Nephropathy progression

Semaglutide → Nephropathy progression

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

La Evidencia Sugiere

  • Semaglutide reduced the risk of primary MACE by 24%.
  • Expanded MACE risk decreased by 20% with semaglutide.
  • Nephropathy risk was reduced by 36%.
who this applies

A quién se aplica

  • Adults with type 2 diabetes.
  • Individuals at high cardiovascular risk.
keep in mind

Tener en Cuenta

  • Results may not apply to all diabetes populations.
  • Further studies are needed to confirm long-term effects.
  • The study did not assess the impact on quality of life.
between the lines

Entre Líneas

  • The study did not show significant effects on cardiovascular death or all-cause mortality.
  • The generalizability of findings may be limited to the specific population studied.
  • Potential confounding factors were not fully explored.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on GLP-1 Receptor Agonists and Cardiovascular Outcomes, GLP-1 Receptor Agonists and Cardiovascular Outcomes.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve cardiovascular outcomes?

Strong Evidence

GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

    EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 1 study

  2. 2

    All-cause mortality

    EvidenceScore™ Strong | EvidenceScore™ 82.9 | weak positive | ConsistencyScore™ Mixed | 1 study

  3. 3

    Cardiovascular death

    EvidenceScore™ Strong | EvidenceScore™ 77.1 | weak negative | ConsistencyScore™ Generally Consistent | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Population details are unavailable.
12 supporting studiesUpdated: Aug 2026
View Full Evidence

Does GLP-1 Receptor Agonists improve kidney function?

Strong Evidence

GLP-1 Receptor Agonists may improve Kidney Function.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    Nephropathy progression

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Population details are unavailable.
5 supporting studiesUpdated: Aug 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Cardiovascular Risk Evidence HubGLP-1 Receptor Agonists Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Semaglutide and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Semaglutide and Nephropathy progressionAll studies on Semaglutide and All-cause mortalityAll studies on Semaglutide and Cardiovascular death

Related research

Read related research summaries.

Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.